XTL Biopharmaceuticals Statistics

Total Valuation

XTL Biopharmaceuticals has a market cap or net worth of ILS 55.53 million. The enterprise value is 49.13 million.

Market Cap	55.53M
Enterprise Value	49.13M

Important Dates

The next estimated earnings date is Wednesday, March 26, 2025.

Earnings Date	Mar 26, 2025
Ex-Dividend Date	n/a

Share Statistics

XTL Biopharmaceuticals has 881.39 million shares outstanding. The number of shares has increased by 7.97% in one year.

Current Share Class	n/a
Shares Outstanding	881.39M
Shares Change (YoY)	+7.97%
Shares Change (QoQ)	+31.89%
Owned by Insiders (%)	14.94%
Owned by Institutions (%)	2.76%
Float	749.74M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	217.28
PB Ratio	2.61
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-12.52
EV / Sales	287.34
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.81

Current Ratio	0.81
Quick Ratio	0.75
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-42.16

Financial Efficiency

Return on equity (ROE) is -25.70% and return on invested capital (ROIC) is -23.73%.

Return on Equity (ROE)	-25.70%
Return on Assets (ROA)	-16.33%
Return on Capital (ROIC)	-23.73%
Revenue Per Employee	34,199
Profits Per Employee	-785,094
Employee Count	5
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +80.00% in the last 52 weeks. The beta is 1.05, so XTL Biopharmaceuticals's price volatility has been similar to the market average.

Beta (5Y)	1.05
52-Week Price Change	+80.00%
50-Day Moving Average	5.31
200-Day Moving Average	7.76
Relative Strength Index (RSI)	51.26
Average Volume (20 Days)	3,214,985

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, XTL Biopharmaceuticals had revenue of ILS 170,996 and -3.93 million in losses. Loss per share was -0.01.

Revenue	170,996
Gross Profit	170,996
Operating Income	-5.80M
Pretax Income	-3.93M
Net Income	-3.93M
EBITDA	n/a
EBIT	-5.80M
Loss Per Share	-0.01

Full Income Statement

Balance Sheet

Cash & Cash Equivalents	6.39M
Total Debt	n/a
Net Cash	6.39M
Net Cash Per Share	0.01
Equity (Book Value)	21.25M
Book Value Per Share	0.02
Working Capital	-1.78M

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-3,391.30%
Pretax Margin	-2,295.65%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

XTL Biopharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.97%
Shareholder Yield	-7.97%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

The last stock split was on June 22, 2009. It was a reverse split with a ratio of 0.2.

Last Split Date	Jun 22, 2009
Split Type	Reverse
Split Ratio	0.2

Scores

XTL Biopharmaceuticals has an Altman Z-Score of -22.47. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-22.47
Piotroski F-Score	n/a